Pharmaceutical composition for the treatment of infectious respiratory diseases caused by influenza and sars-cov-2, among others
AssigneeAlparis, S.A. De C.V.
InventorsGustavo BARRANCO HERNÁNDEZ, Héctor SENOSIAIN ARROYO
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition for nasal delivery comprising a co-amorphous compound of curcumin and arginine for use in the treatment of infectious respiratory diseases and airborne diseases such as the respiratory infection caused by SARS-CoV-2, influenza virus, respiratory syncytial virus and adenovirus, among others.
Claims26
1-29. (canceled)
A pharmaceutical composition for nasal delivery, characterized by comprising a solution of curcumin and arginine formed from a co-amorphous compound of curcumin and arginine having a curcumin:arginine molar ratio from 1:2 to 2:1, and pharmaceutically acceptable excipients, wherein the solution has a pH of 5 to 8 and wherein the pharmaceutically acceptable excipients include:
- (a) at least one buffering agent selected from phosphate salts, carbonate salts and combinations thereof;
- (b) at least one surfactant selected from propylene glycol, polyethylene glycol, PEG400, PEG3500, polyoxyl stearate 400, polysorbate, glycerin, diethylene glycol monoethyl ether (transcutol), polyoxyethylene-polyoxypropylene (lutrol), cetylpyridinium chloride (CPC), cetylpyridinium bromide (CPB), Tween 80;
- Poloxamer 407 and combinations thereof;
- (c) at least one mucoadhesive agent selected from methyl vinyl ether copolymer, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, carbopol, sodium alginate, potassium alginate, magnesium alginate, modified starches, polyvinylpyrrolidone, beta-glucans, chitosan, Eudragit and combinations thereof;
- and (d) vehicles selected from isotonic saline solution, water and seawater.
The use of a curcumin-arginine co-amorphous compound having a molar ratio of curcumin to arginine 1:2, in the manufacture of a medicament useful in the treatment of an infectious disease caused by SARS-CoV2 virus, respiratory syncytial virus, adenovirus or influenza virus, wherein the medicament is in the form of a solution and is adapted for nasal administration.
A curcumin-arginine co-amorphous compound having a molar ratio of curcumin to arginine of 1:2, for use in the treatment of an infectious disease caused by SARS-CoV2 virus, influenza virus, adenovirus and respiratory syncytial virus, wherein co-amorphous compound is formulated in a solution and is adapted for nasal administration.
Dependencies are inferred from the claim text.